Clinical Trials in Boston

Showing 4161-4180 of 13,548 trials

Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders

NCT05120232

This two phase study is testing an online version of a transdiagnostic, cognitive behavioral therapy, against a modified version of that therapy emphasizing positive affect. The first phase of the trial will focus on content development for the modified therapy and the second phase will be a randomized control trial comparing the two.

Anxiety DisordersDepressive Disorder

Boston University Charles River Campus125 participantsStarted Mar 2021

Boston, Massachusetts, United States

Active Not RecruitingPhase 2< 1 mile

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872

This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of other miransertib studies (MK-7075-002 \[NCT03094832\] or ArQule CU/EAP \[NCT03317366\]), and may also enroll participants who are approved for MK-7075-002 but have not yet started miransertib therapy.

Merck Sharp & Dohme LLC60 participantsStarted Nov 2021

Atlanta, Georgia, United States • Boston, Massachusetts, United States • Cincinnati, Ohio, United States +8 more locations

Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Find Trials by Condition in Boston

DS-3201b in Participants With Lymphomas

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Rituximab + Immunotherapy in Follicular Lymphoma

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Framing Eighteen Coils in Cerebral Aneurysms Trial

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation

Different Doses of Naronapride Vs. Placebo in Gastroparesis

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Foot and Ankle Post-operative Oedema Management Using Geko™